Based on Lund University research, group B streptococcus vaccine developer Minervax has now raised $11.4m from investors including Novo.
Minervax, a Denmark-based vaccine developer based on Lund University research, has raised €4.4m ($5m) in a round led by pharmaceutical firm Novo’s antimicrobial resistance-focused Repair Impact Fund. Repair Impact Fund invested $4.1m through the deal, with the remaining $900,000 supplied by venture capital firm Sunstone Life Science Ventures. Founded in 2010, Minervax is working on…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
